TherapeuticsMD Reports Q2 2026 Results: Net Income Falls to $164K, Cash at $9.2M, Strategic Alternatives Under Review
TXMD has more than doubled off its 52-week low of $0.99 on light trading volume (0.4× avg).
Summary
TherapeuticsMD reported Q2 2026 net income of $164 thousand, down from $545 thousand, on lower license revenue. Cash stands at $9.2 million as the company explores strategic alternatives amid going-concern risks.
Key Events · Earnings and Guidance · TXMD
-
Net Income Plunges 70%
Q2 2026 net income from continuing operations fell to $164 thousand from $545 thousand in Q2 2025, reflecting declining royalty revenue and higher costs.
-
License Revenue Declines
License revenue dropped to $869 thousand from $952 thousand year-over-year, attributed to lower sales of licensed products.
-
Cash Position at $9.2 Million
Cash and cash equivalents totaled $9.2 million as of June 30, 2026, providing limited runway against ongoing operating expenses of $1.7 million per quarter.
-
Strategic Alternatives Under Review
The company is actively evaluating a sale, merger, or other business combination, with no assurance of a transaction or timeline for completion.
Analysis · TXMD · Life Sciences
TherapeuticsMD's Q2 2026 results show a sharp decline in net income to $164 thousand from $545 thousand a year ago, driven by lower license revenue and higher operating expenses. With only $9.2 million in cash and a going-concern warning already disclosed, the company's continued evaluation of strategic alternatives—including a potential sale or merger—signals urgency to address its financial trajectory. The results underscore the fragility of its royalty-only business model and the limited runway without a transformative deal.
At the time of this filing, TXMD was trading at $2.07 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $24M. The 52-week trading range was $0.99 to $2.95. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.